Compare XLO & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | MYO |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 36.9M |
| IPO Year | 2021 | 2017 |
| Metric | XLO | MYO |
|---|---|---|
| Price | $8.68 | $0.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $28.00 | $7.67 |
| AVG Volume (30 Days) | 264.1K | ★ 343.7K |
| Earning Date | 03-23-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $43,766,000.00 | ★ $1,000,000,000.00 |
| Revenue This Year | $88.66 | $15.92 |
| Revenue Next Year | N/A | $21.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 589.88 | ★ 40814.79 |
| 52 Week Low | $0.46 | $0.63 |
| 52 Week High | $9.25 | $5.04 |
| Indicator | XLO | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 88.43 | 39.60 |
| Support Level | $0.63 | $0.63 |
| Resistance Level | N/A | $0.78 |
| Average True Range (ATR) | 0.49 | 0.05 |
| MACD | 0.45 | -0.00 |
| Stochastic Oscillator | 90.56 | 38.37 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).